<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="doi: 10.1016/j.mbs.2020.108438108438 : Article Modeling the viral dynamics of SARS-CoV-2" exact="infection" post="WangSunpengaPanYangbcdWangQuanyibcMiaoHongyueBrownAshley N.fRongLibingâ�Ž[a], [b], [c], [d], [e], [f], [g], â�ŽCorresponding"/>
 <result pre="Coronavirus disease 2019 (COVID-19), an infectious disease caused by the" exact="infection" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is"/>
 <result pre="causing the global coronavirus pandemic. The viral dynamics of SARS-CoV-2" exact="infection" post="have not been quantitatively investigated. In this paper, we"/>
 <result pre="use mathematical models to study the pathogenic features of SARS-CoV-2" exact="infection" post="by examining the interaction between the virus, cells and"/>
 <result pre="immune responses. Models are fit to the data of SARS-CoV-2" exact="infection" post="in patients and non-human primates. Data fitting and numerical"/>
 <result pre="fitting and numerical simulation show that viral dynamics of SARS-CoV-2" exact="infection" post="have a few distinct stages. In the initial stage,"/>
 <result pre="time to recovery. These results provide insights for understanding the" exact="infection" post="dynamics and might help develop treatment strategies against COVID-19."/>
 <result pre="insights for understanding the infection dynamics and might help develop" exact="treatment" post="strategies against COVID-19. Highlights â€¢Mathematical models are developed to"/>
 <result pre="data of patients and non-human primates. â€¢Viral dynamics of SARS-CoV-2" exact="infection" post="has a few distinct stages. â€¢Model explains viral rebound"/>
 <result pre="â€¢Model explains viral rebound and prolonged viral persistence. â€¢Implication for" exact="treatment" post="strategies is discussed. 1 Introduction In late December 2019,"/>
 <result pre="(SARS-CoV-2) by the World Health OrganizationÂ [10]. Since then, SARS-CoV-2" exact="infection" post="has been detected in about 190 countries and caused"/>
 <result pre="have significantly low lymphocyte count, possibly due to the direct" exact="infection" post="by coronavirus, leading to cytoplasmic damage and destruction of"/>
 <result pre="develop a vicious cycle to drive lymphocytes to lung for" exact="infection" post="to maintain the viral replication and transmissibility. Currently, there"/>
 <result pre="[47], [48], [49]. However, the within-host viral dynamics of SARS-CoV-2" exact="infection" post="have not been quantitatively investigated. Here we use mathematical"/>
 <result pre="use mathematical models to study the pathogenic characteristics of SARS-CoV-2" exact="infection" post="by examining the interaction between viral replication and the"/>
 <result pre="findings may provide new insights into the pathogenesis of SARS-CoV-2" exact="infection" post="and development of new treatment strategies. 2 Methods 2.1"/>
 <result pre="into the pathogenesis of SARS-CoV-2 infection and development of new" exact="treatment" post="strategies. 2 Methods 2.1 Patient and experiment data The"/>
 <result pre="The viral load data in COVID-19 patients with and without" exact="treatment" post="we analyzed in this paper were from Germany, South"/>
 <result pre="patients were measured every day after onset of symptoms via" exact="reverse transcription polymerase chain reaction" post="(RT-PCR) from specimens of throat swab, sputum, and stool."/>
 <result pre="measured every day after onset of symptoms via reverse transcription" exact="polymerase chain reaction" post="(RT-PCR) from specimens of throat swab, sputum, and stool."/>
 <result pre="sputum, and stool. Seroconversion was detected by IgM and IgG" exact="immunofluorescence" post="and virus neutralization assay within cells expressing the spike"/>
 <result pre="Seroconversion was detected by IgM and IgG immunofluorescence and virus" exact="neutralization assay" post="within cells expressing the spike proteins of SARS-CoV-2Â [14]."/>
 <result pre="viral load was also measured with RT-PCR every day after" exact="diagnosis" post="from samples of nasopharyngeal and oropharyngeal swabs and sputum."/>
 <result pre="p I âˆ’ c V The exact target of SARS-CoV-2" exact="infection" post="is not fully clear. Based on the findings from"/>
 <result pre="The virus is cleared at a constant rate c. SARS-CoV-2" exact="infection" post="can lead to the diffuse alveolar damage (DAD)Â [60]."/>
 <result pre="c V 2.4 The model with a secondary target of" exact="infection" post="Previous studiesÂ [30], [31], [33] detected a large number"/>
 <result pre="SARS-CoV and MERS-CoV patients. A new study also found the" exact="infection" post="of T lymphocytes by SARS-CoV-2Â [35]. We include lymphocytes"/>
 <result pre="rate Î» to represent the recruitment of lymphocytes to the" exact="infection" post="site due to the lung inflammatory response. This was"/>
 <result pre="assumed in the viral dynamic models that studied HIV primary" exact="infection" post="and influenza virus infectionÂ [55], [68]. To minimize the"/>
 <result pre="Pawelek etÂ al. to study the control of influenza virus" exact="infection" post="by the adaptive immune responseÂ [68], it will introduce"/>
 <result pre="target cell populations are infected by SARS-CoV-2 with the same" exact="infection" post="rate Î². Infected cells can be removed by the"/>
 <result pre="target cells/lymphocytes â€&quot; â€&quot; V Virus â€&quot; â€&quot; Î² Viral" exact="infection" post="rate Fitted Î´ I Base death rate of productively"/>
 <result pre="innate immune response Fitted Î» Recruitment of lymphocytes to the" exact="infection" post="site 104 dayâˆ’1 [69] Ïƒ Parameter in the killing"/>
 <result pre="and #14 are from the cases inÂ [14], [54]. The" exact="detection" post="limit is the blue dotted line according toÂ [14]."/>
 <result pre="6 Ã—104 cells/ml. The initial value of lymphocytes at the" exact="infection" post="site is 0. There are no infected cells at"/>
 <result pre="viral load extracted from sputum/saliva. Because much of the early" exact="infection" post="occurs in the lung and only a small proportion"/>
 <result pre="R programming language. 3 Results 3.1 Viral dynamics of SARS-CoV-2" exact="infection" post="We fit each of the three models Eqs. ((1)â€&quot;(3))"/>
 <result pre="models Eqs. ((1)â€&quot;(3)) to the viral load data of SARS-CoV-2" exact="infection" post="in patients from Germany and ChinaÂ [14], [51]. The"/>
 <result pre="of model (3) show that the viral dynamics of SARS-CoV-2" exact="infection" post="can exhibit a few distinct phases (Fig.Â 5A). During"/>
 <result pre="our model, the source of this plateau phase is the" exact="infection" post="of lymphocytes as a secondary target. Without the infection"/>
 <result pre="the infection of lymphocytes as a secondary target. Without the" exact="infection" post="of lymphocytes, SARS-CoV-2 would continue to infect and deplete"/>
 <result pre="from COVID-19 because they could not sustain prolonged life support" exact="treatment" post="due to multiple significant underlying diseasesÂ [80]. The best"/>
 <result pre="The best fits with the model show that the viral" exact="infection" post="rate is significantly higher in URT, but the viral"/>
 <result pre="exhaled air, respiratory droplets or fine-particle aerosolsÂ [81]. The primary" exact="infection" post="of SARS-CoV-2 occurs in the URT while the systematic"/>
 <result pre="If the virus persists at a low level around the" exact="detection" post="limit, the patient may be asymptomatic or only develop"/>
 <result pre="viral load data in a patient from ChinaÂ [51]. The" exact="detection" post="limit is the blue dotted line. 3.3 Potential treatment"/>
 <result pre="The detection limit is the blue dotted line. 3.3 Potential" exact="treatment" post="Lopinavir/ritonavir and remdesivir were suggested to be remedy that"/>
 <result pre="drugs only makes viral load decline slightly faster. However, early" exact="treatment" post="can significantly diminish the time to recovery. SARS-CoV-2 is"/>
 <result pre="IFN antagonistsÂ [53]. We examine the impact of IFN as" exact="treatment" post="intensification with the above antiviral therapy by increasing the"/>
 <result pre="drug efficacy (lopinavir/ritonavir or remdesivir). The result suggests that early" exact="treatment" post="with a combination of IFN and other antiviral drugs"/>
 <result pre="coronavirus infection. The severe acute respiratory syndrome induced by SARS-CoV-2" exact="infection" post="is characterized by over-exuberant inflammatory response. Baricitinib, fedratinib and"/>
 <result pre="secondary target of infection. 4 Discussion Within-host dynamics of SARS-CoV-2" exact="infection" post="have not been quantitatively investigated. We developed mathematical models"/>
 <result pre="model shows that the current best possible control of SARS-CoV-2" exact="infection" post="might be the adaptive immune response of the infected"/>
 <result pre="of the infected individual. This supports the legitimacy of current" exact="treatment" post="with oxygen, mechanical ventilation, corticosteroids and antibiotics that let"/>
 <result pre="three models and the viral load data suggests that SARS-CoV-2" exact="infection" post="might have a secondary target. Without the second target"/>
 <result pre="the data in many patients. The secondary target of SARS-CoV-2" exact="infection" post="might be lymphocytes. Lymphocytopenia is a predominant feature of"/>
 <result pre="of patient #2 inÂ [14], [54] as an example. The" exact="treatment" post="is assumed to be administrated on day 10, 15"/>
 <result pre="MERS-CoV, SARS-CoV, and SARS-CoV-2 infectionÂ [53], [92], [93]. The early" exact="treatment" post="of MERS-CoV infection protected mice from lethal infection but"/>
 <result pre="SARS-CoV-2 infectionÂ [53], [92], [93]. The early treatment of MERS-CoV" exact="infection" post="protected mice from lethal infection but late induction could"/>
 <result pre="The early treatment of MERS-CoV infection protected mice from lethal" exact="infection" post="but late induction could result in serious pneumoniaÂ [92]."/>
 <result pre="SARS-CoV-2 was shown to be more sensitive to type-I IFN" exact="treatment" post="than SARS-CoVÂ [53], [93]. Our simulation shows that the"/>
 <result pre="truncation in its ORF6Â [53]. These alterations might make SARS-CoV-2" exact="infection" post="more sensitive to IFN. IFN was also administrated with"/>
 <result pre="IFN with and without other antiviral drugs to treat SARS-CoV-2" exact="infection" post="in humans. Table 2 Best fits of model (3)"/>
 <result pre="Novel Coronavirus in VietnamNew Engl. J. Med.3829202087287410.1056/NEJMc200127231991079 13RotheC.SchunkM.SothmannP.BretzelG.FroeschlG.WallrauchC.Transmission of 2019-nCoV" exact="infection" post="from an asymptomatic contact in GermanyNew Engl. J. Med.38210202097097110.1056/NEJMc200146832003551"/>
 <result pre="the extrinsic and intrinsic apoptosis pathwaysJ. Infect. Dis.2136201690491410.1093/infdis/jiv38026203058 31GuJ.GongE.ZhangB.ZhengJ.GaoZ.ZhongY.Multiple organ" exact="infection" post="and the pathogenesis of SARSJ. Exp. Med.2023200541542410.1084/jem.2005082816043521 32LiuW.J.ZhaoM.LiuK.XuK.WongG.TanW.T-cell immunity"/>
 <result pre="a novel coronavirusInfect. Dis. Poverty9120202410.1186/s40249-020-00640-332111262 50KimJ.Y.KoJ.H.KimY.KimY.J.KimJ.M.ChungY.S.Viral load kinetics of SARS-CoV-2" exact="infection" post="in first two patients in KoreaJ. Korean Med. Sci.357202010.3346/jkms.2020.35.e86"/>
 <result pre="59HaagmansB.L.KuikenT.MartinaB.E.FouchierR.A.RimmelzwaanG.F.van AmerongenG.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat Med.103200429029310.1038/nm100114981511 60XuZ.ShiL.WangY.ZhangJ.HuangL.ZhangC.Pathological findings of COVID-19 associated with"/>
 <result pre="simian immunodeficiency virusJ. Virol.8232008108410.1128/JVI.02197-0718032490 68PawelekK.A.HuynhG.T.QuinlivanM.CullinaneA.RongL.PerelsonA.S.Modeling within-host dynamics of influenza virus" exact="infection" post="including immune responsesPLoS Comput. Biol.86201210.1371/journal.pcbi.1002588 69WangS.HottzP.SchechterM.RongL.Modeling the slow CD4+"/>
 <result pre="plasma viral dynamics in nonhuman primates provides insights into early" exact="infection" post="and antiviral strategiesProc. Natl. Acad. Sci. USA1143320178847885210.1073/pnas.170401111428765371 78McElreathR.Statistical Rethinking:"/>
 <result pre="Sci. USA1061420095871587610.1073/pnas.080952410619321428 90JaumeM.YipM.S.CheungC.Y.LeungH.L.LiP.H.KienF.Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger" exact="infection" post="of human immune cells via a pH- and cysteine"/>
 <result pre="92ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.IFN-I Response timing relative to virus replication determines MERS coronavirus" exact="infection" post="outcomesJ. Clin. Invest.130920193625363910.1172/jci126363 93ToturaA.L.BaricR.S.SARS Coronavirus pathogenesis: host innate immune"/>
</results>
